Suppr超能文献

不同病原体、感染部位和不良结局的感染性休克患者单核细胞 HLA-DR 表达动力学。

Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes.

机构信息

Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Crit Care. 2020 Mar 20;24(1):110. doi: 10.1186/s13054-020-2830-x.

Abstract

BACKGROUND

Decreased monocytic (m)HLA-DR expression is the most studied biomarker of sepsis-induced immunosuppression. To date, little is known about the relationship between sepsis characteristics, such as the site of infection, causative pathogen, or severity of disease, and mHLA-DR expression kinetics.

METHODS

We evaluated mHLA-DR expression kinetics in 241 septic shock patients with different primary sites of infection and pathogens. Furthermore, we used unsupervised clustering analysis to identify mHLA-DR trajectories and evaluated their association with outcome parameters.

RESULTS

No differences in mHLA-DR expression kinetics were found between groups of patients with different sites of infection (abdominal vs. respiratory, p = 0.13; abdominal vs. urinary tract, p = 0.53) and between pathogen categories (Gram-positive vs. Gram-negative, p = 0.54; Gram-positive vs. negative cultures, p = 0.84). The mHLA-DR expression kinetics differed between survivors and non-survivors (p < 0.001), with an increase over time in survivors only. Furthermore, we identified three mHLA-DR trajectories ('early improvers', 'delayed or non-improvers' and 'decliners'). The probability for adverse outcome (secondary infection or death) was higher in the delayed or non-improvers and decliners vs. the early improvers (delayed or non-improvers log-rank p = 0.03, adjusted hazard ratio 2.0 [95% CI 1.0-4.0], p = 0.057 and decliners log-rank p = 0.01, adjusted hazard ratio 2.8 [95% CI 1.1-7.1], p = 0.03).

CONCLUSION

Sites of primary infection or causative pathogens are not associated with mHLA-DR expression kinetics in septic shock patients. However, patients showing delayed or no improvement in or a declining mHLA-DR expression have a higher risk for adverse outcome compared with patients exhibiting a swift increase in mHLA-DR expression. Our study signifies that changes in mHLA-DR expression over time, and not absolute values or static measurements, are of clinical importance in septic shock patients.

摘要

背景

单核细胞(m)HLA-DR 表达降低是脓毒症引起免疫抑制的最常用生物标志物。迄今为止,人们对脓毒症特征(如感染部位、病原体和疾病严重程度)与 mHLA-DR 表达动力学之间的关系知之甚少。

方法

我们评估了 241 例不同感染部位和病原体的脓毒性休克患者的 mHLA-DR 表达动力学。此外,我们使用无监督聚类分析来识别 mHLA-DR 轨迹,并评估它们与预后参数的关系。

结果

不同感染部位(腹部与呼吸道,p=0.13;腹部与泌尿道,p=0.53)和病原体类别(革兰阳性菌与革兰阴性菌,p=0.54;革兰阳性菌与阴性培养物,p=0.84)的患者组之间,mHLA-DR 表达动力学无差异。幸存者和非幸存者之间的 mHLA-DR 表达动力学存在差异(p<0.001),只有幸存者随时间增加。此外,我们鉴定了三种 mHLA-DR 轨迹(“早期改善者”、“延迟或非改善者”和“下降者”)。与早期改善者相比,延迟或非改善者和下降者的不良结局(继发感染或死亡)的可能性更高(延迟或非改善者对数秩检验 p=0.03,调整后的危险比为 2.0 [95%CI 1.0-4.0],p=0.057;下降者对数秩检验 p=0.01,调整后的危险比为 2.8 [95%CI 1.1-7.1],p=0.03)。

结论

原发感染部位或病原体与脓毒性休克患者的 mHLA-DR 表达动力学无关。然而,与 mHLA-DR 表达迅速增加的患者相比,mHLA-DR 表达延迟或无改善或下降的患者不良结局的风险更高。我们的研究表明,mHLA-DR 表达随时间的变化而不是绝对值或静态测量,在脓毒性休克患者中具有临床重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad41/7082984/601456c6e3d0/13054_2020_2830_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验